Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT07580365
Recruiting Not applicable

VirtualPark_Pediatric

NCT07580365 · tracked via the Priya Life Science Italy tracker
Sponsor
Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato
Phase
Not applicable
Started
2026-06-30
Last updated
2026-08-11

Condition(s) studied

DystrophinopathyMuscular DystrophiesCongenital Myopathies

Investigational drug(s) / intervention(s)

Dual-task cyclingStandard therapy

Dual-task cycling: VirtualPark is a software application connecting to a medical certified cycle/arm ergometer (i.e., TheraTrainer TIGO). The application allows for dual task training. In particular, while cycling, participants can perform one of four different available exercises. Each exercise is focused on a specific cognitive domain: Task 1: visual attention, inhibition and cognitive flexibility; Task 2: working memory; Task 3: inhibition; Task 4: navigation.

Standard therapy: Participants undergo their standard plan: outpatient treatment, if planned, or no treatment.

Study summary

The goal of this clinical trial is to assess the effects of a dual-task, multimodal training program on slowing functional motor decline in children and adolescents with neuromuscular disorders. The main questions it aims to answer are:

Does Virtual Park slow functional motor decline in children and adolescents with neuromuscular diseases compared with standard therapy?

Does Virtual Park contribute to increased engagement and improved neuropsychological function?

If there is a comparison group, Researchers will compare dual-task cycling supported by the Virtual Park application to standard therapy to see whether it improves motor and neuropsychological functions and engagement.

Participants will undergo two phases:

* Phase 1: 3 months of standard therapy;
* Phase 2: 3 months of experimental conditions in which patients undergo a rehabilitative intervention with Virtual Park, 3 times a week.

Eligibility

Sex
ALL
Min age
6 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * availability of a definitive clinical or molecular genetic diagnosis of a neuromuscular disease; * age between 6 years and 17 years and 11 months (inclusive); * height compatible with the use of the Thera-Trainer (minimum 120 cm); * performance Upper Limb Module 2.0 assessment: Entry level \>= 2 Exclusion Criteria: * other concomitant genetic diseases; * presence of visual impairments that prevent access to the experimental virtual reality protocol; * concomitant compromised cardio-respiratory function that contraindicates cycle ergometer training; * severe osteoporosis.

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
IRCCS E. Medea - La Nostra Famiglia Bosisio Parini LC Recruiting
IRCCS Fondazione Stella Maris Pisa PI Recruiting
IRCCS Fondazione Mondino Pavia PV Recruiting
Fondazione Don Gnocchi - Centro "S. Maria al Mare" Salerno SA Suspended

More Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07580365 on ClinicalTrials.gov ↗ ← All trials in Italy